Trial Profile
A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multicenter Study to Assess Efficacy and Safety of VESIcare(Solifenacin Succinate) to Improve Urinary Continence of Subjects After Robotic Assisted Radical Prostatectomy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2018
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary)
- Indications Urinary incontinence
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.